Telix Pharmaceuticals (NASDAQ:TLX) Sets New 1-Year High - What's Next?

Key Points

• Telix Pharmaceuticals shares reached a new 52-week high of $12.48, up from a prior close of $11.98, with trading volume near 394,000 shares.
• Analyst sentiment remains positive, with a consensus rating of “Moderate Buy” and an average price target of $20.40. Recent targets include $22 from Wedbush and $20 from HC Wainwright.
• Institutional interest increased, with several investors—including XY Capital, Bank of America, and Private Advisor Group—substantially raising their positions in the company.

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) reached a new 52-week high on Wednesday . The stock traded as high as $12.48 and last traded at $12.3940, with a volume of 393964 shares. The stock had previously closed at $11.98.

Analysts Set New Price Targets

TLX has been the subject of a number of recent research reports. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a report on Friday, August 21st. Citigroup reissued a "buy" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Wedbush restated an "outperform" rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Royal Bank Of Canada cut Telix Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research report on Friday, July 17th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $20.40.

Telix Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. The company's 50-day moving average price is $11.23 and its 200 day moving average price is $10.06.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TLX. XY Capital Ltd raised its stake in Telix Pharmaceuticals by 468.0% during the second quarter. XY Capital Ltd now owns 71,291 shares of the company's stock valued at $822,000 after purchasing an additional 58,739 shares in the last quarter. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Telix Pharmaceuticals during the second quarter valued at approximately $1,731,000. Bank of America Corp DE increased its stake in shares of Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company's stock valued at $96,000 after buying an additional 8,423 shares during the period. Lazard Asset Management LLC increased its holdings in Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company's stock valued at $2,775,000 after buying an additional 39,400 shares during the period. Finally, Private Advisor Group LLC grew its stake in Telix Pharmaceuticals by 276.3% in the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock valued at $1,669,000 after purchasing an additional 128,070 shares during the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.